| 摘要 |
Compositions, kits and methods for inhibiting cancer cell (e.g., breast cancer cell) growth and treating a subject with cancer (e.g., breast cancer) include a therapeutically effective amount of an LBH inhibitor for inhibiting cancer cell growth and a pharmaceutically acceptable carrier, and/or a therapeutically effective amount of Wnt7a protein or nucleic acids encoding Wnt7a protein for inhibiting cancer cell growth and a pharmaceutically acceptable carrier. Methods of treating a subject having cancer (e.g., estrogen receptor negative basal-type breast cancer) include administering to the subject a composition including a pharmaceutical carrier and at least one of: an LBH inhibitor, a WNT7a protein, and a nucleic acid encoding WNT7a protein in an amount effective for inhibiting growth of cancer cells in the subject. Methods of detecting the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in a subject include obtaining a biological sample from the subject; contacting the sample with at least one reagent that detects presence of LBH expression; measuring the level of LBH expression in the biological sample; and correlating overexpression of LBH with the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in the subject. Kits for detecting the presence of basal-type breast cancer in a subject include at least one reagent for detecting the presence of LBH expression in a biological sample from the subject and instructions for use.
|
